SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
SEC Accession No. 0001104659-23-031531
Filing Date
2023-03-13
Accepted
2023-03-13 08:01:26
Documents
4
Group Members
NOVARTIS AGNOVARTIS PHARMA AG

Document Format Files

Seq Description Document Type Size
1 SC 13G tm239106d1_sc13g.htm SC 13G 75145
2 EXHIBIT 1 tm239106d1_ex99-1.htm EX-99.1 10631
3 EXHIBIT 2 tm239106d1_ex99-2.htm EX-99.2 37011
4 EXHIBIT 3 tm239106d1_ex99-3.htm EX-99.3 7299
  Complete submission text file 0001104659-23-031531.txt   131638
Mailing Address C/O NOVARTIS INTERNATIONAL AG WSJ-200.220 CH-4002 BASEL V8 0000000000
Business Address C/O NOVARTIS INTERNATIONAL AG WSJ-200.220 CH-4002 BASEL V8 0000000000 41-61-324-6210
Novartis Bioventures Ltd (Filed by) CIK: 0001297709 (see all company filings)

IRS No.: 000000000 | State of Incorp.: D0 | Fiscal Year End: 1231
Type: SC 13G

Mailing Address BAHNHOFSTRASSE 7 ZUG V8 6300
Business Address BAHNHOFSTRASSE 7 ZUG V8 6300 617-937-2423
Oculis Holding AG (Subject) CIK: 0001953530 (see all company filings)

IRS No.: 000000000 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-94014 | Film No.: 23725771
SIC: 2834 Pharmaceutical Preparations